Desq Long
Sign in

Company

NewAmsterdam Pharma Co N.V.

NAMS · CIK 0001936258

SEC FORM 4
$226,500.00

NewAmsterdam Pharma Co N.V. (NAMS)

Purchase of 10,000 shares at $22.65 per share.

Reporting Person Davidson Michael H. · Officer Title Chief Executive Officer · Transaction Code P

Traded Sep 14, 2026 · Disclosed Sep 15, 2026

Source: SEC Form 4 · 0001193125-26-391985 · filed 2026-09-15 · View filing →

SEC FORM 4
$40,512.00

NewAmsterdam Pharma Co N.V. (NAMS)

Sale of 1,600 shares at $25.32 per share.

Reporting Person Smither John W · Transaction Code S

Traded Sep 4, 2026 · Disclosed Sep 9, 2026

Source: SEC Form 4 · 0001193125-26-386508 · filed 2026-09-09 · View filing →

SEC FORM 4
$0.00

NewAmsterdam Pharma Co N.V. (NAMS)

Acquisition (code A) of 3,200 shares at $0 per share.

Reporting Person Gunning Robert William · Officer Title Vice President, Controller · Transaction Code A

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001193125-26-381953 · filed 2026-09-03 · View filing →

SEC FORM 4
—

NewAmsterdam Pharma Co N.V. (NAMS)

Acquisition (code M) of 125,000 shares; price not stated (see filing).

Reporting Person Kastelein Johannes Jacob Pieter · Officer Title Chief Scientific Officer · Transaction Code M

Traded Aug 24, 2026 · Disclosed Aug 25, 2026

Source: SEC Form 4 · 0001193125-26-365202 · filed 2026-08-25 · View filing →

SEC FORM 4
$3,363,750.00

NewAmsterdam Pharma Co N.V. (NAMS)

Sale of 125,000 shares at $26.91 per share.

Reporting Person Kastelein Johannes Jacob Pieter · Officer Title Chief Scientific Officer · Transaction Code S

Traded Aug 24, 2026 · Disclosed Aug 25, 2026

Source: SEC Form 4 · 0001193125-26-365202 · filed 2026-08-25 · View filing →